Functional Analysis of Polymorphisms in the COX-2 Gene and Risk of Lung Cancer

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2017 Apr 18

PMID 28413655

Citations 6

Authors

Joyce L Moraes

Amanda B Moraes

Veronica Aran

Marcelo R Alves

Luciene Schluckbier

Mariana Duarte

Edson Toscano

Mauro Zamboni

Cinthya Sternberg

Emanuela de Moraes

Jose R Lapa E Silva

Carlos Gil Ferreira

Affiliations

Soon will be listed here.

Abstract

The enzyme cyclooxygenase 2 (COX-2) is known to be involved in tumorigenesis and metastasis in certain types of cancer. Nevertheless, the prognostic value of COX-2 overexpression and its polymorphisms in patients with non-small cell lung cancer (NSCLC) have yet to be fully elucidated. The aim of the present study was to investigate the association between the three most commonly studied COX-2 gene polymorphisms (-1195 G/A, -765 G/C and 8473 T/C) with COX-2 expression and lung cancer risk in a Brazilian cohort. In the present hospital based, case-control retrospective study, 104 patients with NSCLC and 202 cancer free control subjects were genotyped for -1195 G/A, -765 G/C and 8473 T/C polymorphisms using allelic discrimination with a reverse transcription quantitative polymerase chain reaction method. COX-2 mRNA expression was analyzed in surgically resected tumors from 34 patients with NSCLC. The results revealed that COX-2 expression levels were higher in tumor tissue compared with normal lung tissue. However, this overexpression of COX-2 was not associated with the patient outcome, and furthermore, none of the analyzed polymorphisms were associated with the risk of developing lung cancer, COX-2 overexpression, or the overall survival of the patients with NSCLC. Taken together, the findings described in the present study do not support a major role for COX-2 polymorphisms and COX-2 overexpression in lung carcinogenesis within the Brazilian population.

Citing Articles

COX-2 in lung cancer: Mechanisms, development, and targeted therapies.

Liu X, Zhang J, Sun W, Cao J, Ma Z Chronic Dis Transl Med. 2024; 10(4):281-292.

PMID: 39429482 PMC: 11483542. DOI: 10.1002/cdt3.120.

The Association Between Cyclooxygenase-2 -1195G/A (rs689466) Gene Polymorphism and the Clinicopathology of Lung Cancer in the Japanese Population: A Case-Controlled Study.

Sun R, Tanino R, Tong X, Isomura M, Chen L, Hotta T Front Genet. 2022; 13:796444.

PMID: 35450217 PMC: 9016323. DOI: 10.3389/fgene.2022.796444.

Strain-specific behavior of Mycobacterium tuberculosis in A549 lung cancer cell line.

Hadifar S, Mostafaei S, Behrouzi A, Fateh A, Riahi P, Siadat S BMC Bioinformatics. 2021; 22(1):154.

PMID: 33765916 PMC: 7992940. DOI: 10.1186/s12859-021-04100-z.

COX-2 rs5275 and rs689466 polymorphism and risk of lung cancer: A PRISMA-compliant meta-analysis.

Li J, Lu X, Zou X, Jiang Y, Yao J, Liu H Medicine (Baltimore). 2018; 97(35):e11859.

PMID: 30170377 PMC: 6393127. DOI: 10.1097/MD.0000000000011859.

Association between cyclooxygenase-2 (COX-2) 8473 T > C polymorphism and cancer risk: a meta-analysis and trial sequential analysis.

Li Q, Ma C, Zhang Z, Chen S, Zhi W, Zhang L BMC Cancer. 2018; 18(1):847.

PMID: 30143023 PMC: 6109290. DOI: 10.1186/s12885-018-4753-3.

References

Nam E, Lee S, Im S, Kim D, Lee K, Sung S . Expression of cyclooxygenase-2 in human breast cancer: relationship with HER-2/neu and other clinicopathological prognostic factors. Cancer Res Treat. 2009; 37(3):165-70. PMC: 2785410. DOI: 10.4143/crt.2005.37.3.165. View

Tang Z, Nie Z, Pan Y, Zhang L, Gao L, Zhang Q . The Cox-2 -1195 G > A polymorphism and cancer risk: a meta-analysis of 25 case-control studies. Mutagenesis. 2011; 26(6):729-34. DOI: 10.1093/mutage/ger040. View

Koki A, Masferrer J . Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002; 9(2 Suppl):28-35. DOI: 10.1177/107327480200902S04. View

Tsujii M, Kawano S, DuBois R . Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997; 94(7):3336-40. PMC: 20370. DOI: 10.1073/pnas.94.7.3336. View

Wistuba I, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S . Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res. 2000; 6(7):2604-10. PMC: 5164924. View

Wang X, Huang M, Zhang X, Hua R, Guo W . COX-2-765G>C polymorphism increases the risk of cancer: a meta-analysis. PLoS One. 2013; 8(9):e73213. PMC: 3762903. DOI: 10.1371/journal.pone.0073213. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Bhat I, Rasool R, Qasim I, Masoodi K, Paul S, Bhat B . COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer. Tumour Biol. 2014; 35(11):11209-18. DOI: 10.1007/s13277-014-2420-0. View

Fu J, Masferrer J, Seibert K, Raz A, NEEDLEMAN P . The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990; 265(28):16737-40. View

10.

Tanabe T, Tohnai N . Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 2002; 68-69:95-114. DOI: 10.1016/s0090-6980(02)00024-2. View

11.

Kristinsson J, van Westerveld P, Te Morsche R, Roelofs H, Wobbes T, Witteman B . Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J Gastroenterol. 2009; 15(28):3493-7. PMC: 2715974. DOI: 10.3748/wjg.15.3493. View

12.

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

13.

Wang D, DuBois R . Eicosanoids and cancer. Nat Rev Cancer. 2010; 10(3):181-93. PMC: 2898136. DOI: 10.1038/nrc2809. View

14.

Bi N, Yang M, Zhang L, Chen X, Ji W, Ou G . Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res. 2010; 16(8):2383-90. DOI: 10.1158/1078-0432.CCR-09-2793. View

15.

Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S . Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998; 58(17):3761-4. View

16.

Peto R, Darby S, Deo H, Silcocks P, Whitley E, DOLL R . Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000; 321(7257):323-9. PMC: 27446. DOI: 10.1136/bmj.321.7257.323. View

17.

Papafili A, Hill M, Brull D, McAnulty R, Marshall R, Humphries S . Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol. 2002; 22(10):1631-6. DOI: 10.1161/01.atv.0000030340.80207.c5. View

18.

Guo Y, Zhang X, Tan W, Miao X, Sun T, Zhao D . Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms. Pharmacogenet Genomics. 2007; 17(3):197-205. DOI: 10.1097/FPC.0b013e328010bda1. View

19.

Krzystyniak K . Current strategies for anticancer chemoprevention and chemoprotection. Acta Pol Pharm. 2003; 59(6):473-8. View

20.

Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T . Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis. 2006; 28(6):1197-201. DOI: 10.1093/carcin/bgl242. View